These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
591 related articles for article (PubMed ID: 20347032)
1. Concomitant detection of beta-amyloid peptides with N-terminal truncation and different C-terminal endings in cortical plaques from cases with Alzheimer's disease, senile monkeys and triple transgenic mice. Härtig W; Goldhammer S; Bauer U; Wegner F; Wirths O; Bayer TA; Grosche J J Chem Neuroanat; 2010 Sep; 40(1):82-92. PubMed ID: 20347032 [TBL] [Abstract][Full Text] [Related]
2. High sensitivity analysis of amyloid-beta peptide composition in amyloid deposits from human and PS2APP mouse brain. Güntert A; Döbeli H; Bohrmann B Neuroscience; 2006 Dec; 143(2):461-75. PubMed ID: 17008022 [TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of Tau at S422 is enhanced by Abeta in TauPS2APP triple transgenic mice. Grueninger F; Bohrmann B; Czech C; Ballard TM; Frey JR; Weidensteiner C; von Kienlin M; Ozmen L Neurobiol Dis; 2010 Feb; 37(2):294-306. PubMed ID: 19781645 [TBL] [Abstract][Full Text] [Related]
4. Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. Lewis HD; Beher D; Smith D; Hewson L; Cookson N; Reynolds DS; Dawson GR; Jiang M; Van der Ploeg LH; Qian S; Rosahl TW; Kalaria RN; Shearman MS Neurobiol Aging; 2004 Oct; 25(9):1175-85. PubMed ID: 15312963 [TBL] [Abstract][Full Text] [Related]
5. Deposition of mouse amyloid beta in human APP/PS1 double and single AD model transgenic mice. van Groen T; Kiliaan AJ; Kadish I Neurobiol Dis; 2006 Sep; 23(3):653-62. PubMed ID: 16829076 [TBL] [Abstract][Full Text] [Related]
6. In vivo labelling of hippocampal beta-amyloid in triple-transgenic mice with a fluorescent acetylcholinesterase inhibitor released from nanoparticles. Härtig W; Kacza J; Paulke BR; Grosche J; Bauer U; Hoffmann A; Elsinghorst PW; Gütschow M Eur J Neurosci; 2010 Jan; 31(1):99-109. PubMed ID: 20092557 [TBL] [Abstract][Full Text] [Related]
7. Powerful beneficial effects of benfotiamine on cognitive impairment and beta-amyloid deposition in amyloid precursor protein/presenilin-1 transgenic mice. Pan X; Gong N; Zhao J; Yu Z; Gu F; Chen J; Sun X; Zhao L; Yu M; Xu Z; Dong W; Qin Y; Fei G; Zhong C; Xu TL Brain; 2010 May; 133(Pt 5):1342-51. PubMed ID: 20385653 [TBL] [Abstract][Full Text] [Related]
8. Oligomers of beta-amyloid are sequestered into and seed new plaques in the brains of an AD mouse model. Gaspar RC; Villarreal SA; Bowles N; Hepler RW; Joyce JG; Shughrue PJ Exp Neurol; 2010 Jun; 223(2):394-400. PubMed ID: 19744481 [TBL] [Abstract][Full Text] [Related]
9. Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Shin RW; Ogino K; Shimabuku A; Taki T; Nakashima H; Ishihara T; Kitamoto T Acta Neuropathol; 2007 Jun; 113(6):627-36. PubMed ID: 17431643 [TBL] [Abstract][Full Text] [Related]
11. Isoaspartate formation and neurodegeneration in Alzheimer's disease. Shimizu T; Watanabe A; Ogawara M; Mori H; Shirasawa T Arch Biochem Biophys; 2000 Sep; 381(2):225-34. PubMed ID: 11032409 [TBL] [Abstract][Full Text] [Related]
12. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910 [TBL] [Abstract][Full Text] [Related]
13. Cholinergic neuropathology in a mouse model of Alzheimer's disease. German DC; Yazdani U; Speciale SG; Pasbakhsh P; Games D; Liang CL J Comp Neurol; 2003 Aug; 462(4):371-81. PubMed ID: 12811807 [TBL] [Abstract][Full Text] [Related]
14. Relative paucity of tau accumulation in the small areas with abundant Abeta42-positive capillary amyloid angiopathy within a given cortical region in the brain of patients with Alzheimer pathology. Oshima K; Akiyama H; Tsuchiya K; Kondo H; Haga C; Shimomura Y; Iseki E; Uchikado H; Kato M; Niizato K; Arai H Acta Neuropathol; 2006 Jun; 111(6):510-8. PubMed ID: 16718347 [TBL] [Abstract][Full Text] [Related]
15. Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease. Hashimoto T; Ogino K; Shin RW; Kitamoto T; Kikuchi T; Shimizu N Neurosci Lett; 2010 Jan; 469(2):273-7. PubMed ID: 20025930 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and amyloid plaque targeting ability of a novel peptide-based magnetic resonance contrast agent in wild-type and Alzheimer's disease transgenic mice. Kandimalla KK; Wengenack TM; Curran GL; Gilles EJ; Poduslo JF J Pharmacol Exp Ther; 2007 Aug; 322(2):541-9. PubMed ID: 17505020 [TBL] [Abstract][Full Text] [Related]
17. Characterization of Abeta11-40/42 peptide deposition in Alzheimer's disease and young Down's syndrome brains: implication of N-terminally truncated Abeta species in the pathogenesis of Alzheimer's disease. Liu K; Solano I; Mann D; Lemere C; Mercken M; Trojanowski JQ; Lee VM Acta Neuropathol; 2006 Aug; 112(2):163-74. PubMed ID: 16865398 [TBL] [Abstract][Full Text] [Related]